Our story
After decades leading commercial expansion for emerging biotechs, we saw the same story repeat itself: launching a single life-changing therapy in new markets meant building an entire infrastructure from scratch , legal entities, licenses, teams, logistics for just one product. We lived this challenge firsthand. Each launch demanded full P&L responsibility for a single asset, with high uncertainty and significant upfront investment. At the same time, only about 30% of orphan drugs approved in the U.S. ever become available across Europe, the Middle East, and Eurasia, leaving millions of rare-disease patients without access to approved therapies. And yet, there was no scalable, license-ready solution to help biotech innovators enter these regions efficiently, compliantly, and without prohibitive cost or risk. So we decided to create one. That’s how Mirava Bio was born, to rethink how rare-disease therapies reach patients, what we call in the industry the “go-to-market models”. We built a shared commercialization platform designed specifically for ATMPs and rare-disease biotechs: a model that mutualizes infrastructure, licenses, and expertise, providing early-stage companies with the flexibility to generate early revenues, demonstrate value, and, most importantly, serve patients who cannot wait.
